HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ONMD
OneMedNet Corporation
There isn't enough reported data to score ONMD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ONMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
ONMD's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ONMD PE Valuation
ONMD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ONMD Forward outlook
There aren't enough analyst estimates for ONMD to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ONMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.50 | -$0.20 |
| Q1 2026 | -$0.40 | +$3.10 |
| Q4 2025 | -$0.60 | +$3.20 |
| Q3 2025 | -$0.70 | +$48.80 |
| Q2 2025 | -$1.30 | +$48.70 |
ONMD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ONMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ONMD on profitability, with a higher operating margin.
ONMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $292K | +88% |
| Q1 2026 | $96K | -30% |
| Q4 2025 | $891K | +3327% |
| Q3 2025 | $177K | +25% |
| Q2 2025 | $155K | -32% |
| Q1 2025 | $137K | -45% |
| Q4 2024 | $26K | -92% |
ONMD's revenue is growing: $292,000 last quarter, up 88% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -774% | +557 points |
| Q1 2026 | -2658% | -1035 points |
| Q4 2025 | -346% | +9908 points |
| Q3 2025 | -1263% | +418 points |
| Q2 2025 | -1331% | -250 points |
| Q1 2025 | -1623% | -776 points |
| Q4 2024 | -10254% | -8697 points |
| Q3 2024 | -1681% | N/A |
ONMD's operating margin was −774% last quarter, up 557 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ONMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
ONMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.9M | +$403K |
| Q1 2026 | -$1.5M | +$409K |
| Q4 2025 | -$1.7M | +$344K |
| Q3 2025 | -$1.6M | +$354K |
| Q2 2025 | -$2.3M | -$780K |
| Q1 2025 | -$2M | -$400K |
| Q4 2024 | -$2.1M | +$1.9M |
| Q3 2024 | -$1.9M | -$1.8M |
ONMD has burned cash in almost every quarter: −$7M over the past year, against −$8M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ONMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ONMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +270K shares |
| 1 year | +51% | +2M shares |
| 3 years | +288% | +4.3M shares |
ONMD has 6M diluted shares, up 51% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ONMD Net Leverage
ONMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ONMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 29.2 | Neutral |
ONMD's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ONMD PE vs Healthcare Sector
ONMD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ONMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.01 | 6.8% above |
| 20 week MA | $6.04 | 11% below |
| 50 week MA | $7.98 | 33% below |
| 100 week MA | $8.66 | 38% below |
| 200 week MA | $29.9 | 82% below |
ONMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ONMD on returns for 2026, with the stronger performance.
ONMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $99.4 | $101.0 | +1.6% |
| 2022 | $101.0 | $104.4 | +3.4% |
| 2023 | $104.4 | $8.10 | -92% |
| 2024 | $8.10 | $13.3 | +64% |
| 2025 | $13.3 | $12.7 | -4.5% |
| 2026 YTD | $12.7 | $5.35 | -58% |
ONMD is down 58% so far in 2026, after finishing higher in three of the previous five years.